ES2523024T3 - Tratamiento de glucogenosis de tipo II - Google Patents

Tratamiento de glucogenosis de tipo II Download PDF

Info

Publication number
ES2523024T3
ES2523024T3 ES07001091.3T ES07001091T ES2523024T3 ES 2523024 T3 ES2523024 T3 ES 2523024T3 ES 07001091 T ES07001091 T ES 07001091T ES 2523024 T3 ES2523024 T3 ES 2523024T3
Authority
ES
Spain
Prior art keywords
glycogenosis
type
human
treatment
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES07001091.3T
Other languages
English (en)
Spanish (es)
Inventor
Yuan-Tsong Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2523024(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2523024T3 publication Critical patent/ES2523024T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES07001091.3T 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II Expired - Lifetime ES2523024T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
US219237P 2000-07-18

Publications (1)

Publication Number Publication Date
ES2523024T3 true ES2523024T3 (es) 2014-11-20

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
ES07001091.3T Expired - Lifetime ES2523024T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES18194771T Expired - Lifetime ES2799882T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES01951000T Expired - Lifetime ES2277931T3 (es) 2000-07-18 2001-07-10 Tratamiento de la glucogenesis de tipo ii.
ES16178390T Expired - Lifetime ES2700865T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES14167882.1T Expired - Lifetime ES2599401T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES18194771T Expired - Lifetime ES2799882T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES01951000T Expired - Lifetime ES2277931T3 (es) 2000-07-18 2001-07-10 Tratamiento de la glucogenesis de tipo ii.
ES16178390T Expired - Lifetime ES2700865T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES14167882.1T Expired - Lifetime ES2599401T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II

Country Status (17)

Country Link
US (10) US7056712B2 (enExample)
EP (4) EP2767291B1 (enExample)
JP (10) JP5113312B2 (enExample)
AT (1) ATE355075T1 (enExample)
AU (3) AU2001271941B2 (enExample)
BR (1) BR0113006A (enExample)
CA (1) CA2416492C (enExample)
CY (2) CY1120977T1 (enExample)
DE (1) DE60126947T2 (enExample)
DK (5) DK2767291T3 (enExample)
ES (5) ES2523024T3 (enExample)
LT (3) LT3108895T (enExample)
MX (1) MXPA03000474A (enExample)
PT (5) PT3449934T (enExample)
SI (3) SI2767291T1 (enExample)
TW (1) TWI280882B (enExample)
WO (1) WO2002005841A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271941B2 (en) 2000-07-18 2007-03-01 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
AU2002256423B2 (en) * 2001-04-30 2008-07-24 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
US20040248262A1 (en) * 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CA2568150A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
BRPI0912225A2 (pt) 2008-05-07 2018-03-20 Zystor Therapeutics, Inc. peptídeos de direcionamento lisossomais e usos dos mesmos
WO2010005565A2 (en) * 2008-07-08 2010-01-14 Duke University Method of treating glycogen storage disease
EP3075386B1 (en) * 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
CA2901978A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
EP3622821A1 (en) 2013-05-15 2020-03-18 Regents of the University of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
SI4273241T1 (sl) 2014-09-30 2025-03-31 Amicus Therapeutics, Inc. Zelo močna kislinska alfa-glukozidaza z okrepljenimi ogljikovimi hidrati
US11096991B2 (en) 2015-05-07 2021-08-24 The University Of Tokyo Nanoreactor using polyion complex polymersomes, and method for producing same
MA44747A (fr) * 2015-08-31 2019-03-06 Univ Duke Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
NZ786723A (en) 2016-03-30 2025-07-25 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
IL262211B2 (en) 2016-04-15 2024-01-01 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
DK3624831T5 (da) 2017-05-15 2024-09-02 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
PT2020438T (pt) * 1998-12-07 2018-07-13 Genzyme Corp Tratamento da doença de pompe
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
AU2001271941B2 (en) * 2000-07-18 2007-03-01 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
ES2799882T3 (es) 2020-12-22
EP3108895B1 (en) 2018-09-19
SI3108895T1 (sl) 2019-01-31
US20150004152A1 (en) 2015-01-01
PT2767291T (pt) 2016-10-25
US20160184410A1 (en) 2016-06-30
JP2014185187A (ja) 2014-10-02
PT1782825E (pt) 2014-11-04
JP2013231081A (ja) 2013-11-14
AU2010200487A1 (en) 2010-03-04
US20100254966A1 (en) 2010-10-07
CY1120977T1 (el) 2019-12-11
EP3108895A1 (en) 2016-12-28
US20080175833A1 (en) 2008-07-24
CY1123084T1 (el) 2021-10-29
JP5792774B2 (ja) 2015-10-14
EP1301201B1 (en) 2007-02-28
DK3108895T3 (en) 2018-11-26
DE60126947T2 (de) 2007-10-31
US9370556B2 (en) 2016-06-21
JP2016056206A (ja) 2016-04-21
DK2767291T3 (en) 2016-12-05
US20020110551A1 (en) 2002-08-15
PT3108895T (pt) 2018-12-18
JP2017137357A (ja) 2017-08-10
JP2018002749A (ja) 2018-01-11
JP2020019822A (ja) 2020-02-06
JP2004503598A (ja) 2004-02-05
LT3449934T (lt) 2020-08-10
HK1054690A1 (en) 2003-12-12
WO2002005841A1 (en) 2002-01-24
CA2416492A1 (en) 2002-01-24
AU7194101A (en) 2002-01-30
MXPA03000474A (es) 2003-10-06
DK3449934T3 (da) 2020-06-29
DE60126947D1 (de) 2007-04-12
US20130195834A1 (en) 2013-08-01
DK1301201T3 (da) 2007-04-02
ES2700865T3 (es) 2019-02-19
US10792341B2 (en) 2020-10-06
JP5113312B2 (ja) 2013-01-09
HK1197656A1 (en) 2015-02-06
JP2018199721A (ja) 2018-12-20
EP2767291A3 (en) 2014-10-08
ES2599401T3 (es) 2017-02-01
JP6163216B2 (ja) 2017-07-12
ATE355075T1 (de) 2006-03-15
TWI280882B (en) 2007-05-11
US20210169996A1 (en) 2021-06-10
SI3449934T1 (sl) 2020-09-30
ES2277931T3 (es) 2007-08-01
US9907839B2 (en) 2018-03-06
DK1782825T3 (da) 2014-11-03
BR0113006A (pt) 2004-10-19
US20050123531A1 (en) 2005-06-09
CA2416492C (en) 2008-04-29
JP2008081507A (ja) 2008-04-10
EP1301201A1 (en) 2003-04-16
US8900552B2 (en) 2014-12-02
JP2012006953A (ja) 2012-01-12
EP3449934A1 (en) 2019-03-06
SI2767291T1 (sl) 2016-11-30
HK1103363A1 (en) 2007-12-21
US20180185457A1 (en) 2018-07-05
PT3449934T (pt) 2020-06-25
AU2001271941B2 (en) 2007-03-01
US7056712B2 (en) 2006-06-06
US20120058132A1 (en) 2012-03-08
EP3449934B1 (en) 2020-05-20
EP2767291A2 (en) 2014-08-20
PT1301201E (pt) 2007-03-30
LT2767291T (lt) 2016-11-25
LT3108895T (lt) 2018-11-26
EP2767291B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
ES2523024T3 (es) Tratamiento de glucogenosis de tipo II
Polani et al. Progressive cardiomyopathic lentiginosis
Lawson et al. Three-year sustained benefit from enhanced external counterpulsation in chronic angina pectoris
ATE6251T1 (de) Acylpeptide und pharmazeutische praeparate davon, sowie deren herstellung und verwendung.
Alhady et al. Total paralysis regime in severe tetanus
MX9305855A (es) Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
Torkut et al. Double reversing Z-plasty for correction of transverse facial cleft
Hernández et al. Ehlers‐Danlos features with progeroid facies and mild mental retardation: Further delineation of the syndrome
Koné‐Paut et al. Keratitis, ichthyosis, and deafness (KID) syndrome in half sibs
Ramos et al. The protective effect of carnitine in human diphtheric myocarditis
KR890006815A (ko) 산성 섬유아세포 생장인자의 돌연변이체
Kaya et al. The early erosive vesicular stage of lipoid proteinosis: clinical and histopathological features.
Martin et al. Case of myxoedema with a huge pericardial effusion and cardiac tamponade
Zheng et al. Successful treatment of acquired cutis laxa with urticarial eruption by diphenyl sulfone.
ORIMO et al. Thyrocalcitonin and age
Creamer et al. Multiple endocrine neoplasia type 1 presenting as rosacea
Achenbach et al. Paracoccidioidomycosis: unusual clinical presentation and utility of computerized tomography scanning for diagnosis
Yao et al. Pseudocholinesterase hyperactivity with succinylcholine resistance: an unusual cause of difficult intubation
BR0208140A (pt) Polipeptìdeo, agente imunoterapêutico para o tratamento de psorìase, sequência de ácido nucléico isolada ou seu complemento, vetores de filamento único, e de filamento duplo, sequência de ácido nucléico isolada ou variante imunogênica da mesma, métodos para a produção de polipeptìdeos, e para o tratamento e a remissão clìnica de psorìase, e, célula hospedeira microbiana
Ehinger Uptake of tritiated glycine into neurons of the human retina
Widiono et al. A male patient with amyand hernia: A case report and literature review
Franklin Intranasal Treatment By Ionization In Hay Fever, Vasomotor Rhinitis, And Ozaena
Gold Still's disease with pseudoxanthoma elasticum
Reed et al. Dermatoglyphic heterogeneity in mongolis with congenital heart disease
Turk Antibiotic Sensitivity Testing